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Erratum
Randomised trial of four-drug vs less intensive two-drug
chemotherapy in the palliative treatment of patients with smal
cell lung cancer (SCLC) and poor prognosis
Medical Research Council Lung Cancer Working Party
(prepared on behalf of the working party and its
collaborators by NM Bleehen, DJ Girling, P Hopwood, G
Lallemand, D Machin, RJ Stephens and AJ Bailey)
British Journal of Cancer, 1996; 73: 406-413
In the publication of the above paper, a proof correction on
Table IV was overlooked. The corrected table is shown
below:
Table IV Main adverse reactions reported by clinicians during the first 3 months
Estimated percentage ofpatients
Adverse reaction ECMV EV HRa 95% CI
Alopecia (90) (97) 1.02 0.77- 1.35
Anorexia (48) (43) 1.14 0.75- 1.76
Nausea (61) (48) 1.43 0.98-2.09
Vomiting (51) (44) 1.23 0.82-1.85
Dysphagia (38) (27) 1.42 0.86-2.34
Sore mouth/mucositis (54) (34) 1.99 1.30-3.05
Numbness (38) (35) 1.16 0.73- 1.85
Haematological WHO grade 2 or worse (38) (21) 2.17 1.27-3.70
Anaemia (32) (19) 1.97 1.11 -3.52
Leucopenia (16) (4) 4.18 1.65- 10.58
Thrombocytopenia (4) (2) 2.30 0.46-11.45
aHR > 1.0 indicates an advantage to the EV regimen.